EC Number   |
Specific Activity Minimum [µmol/min/mg] |
Specific Activity Maximum [µmol/min/mg] |
Reference |
|---|
    3.5.4.5 | 105 |
- |
- |
209665 |
| 3.5.4.5 | 118 |
- |
- |
209653 |
| 3.5.4.5 | 238 |
- |
- |
209667 |
| 3.5.4.5 | 570 |
- |
- |
209667 |
| 3.5.4.5 | 0.7254 |
- |
activity in non-small cell lung cancer patients carrying the Lys27Gln polymorphism and the Gln27Gln polymorphism, in 50 mM beta-mercaptoethanol, 0.1 M Tris-HCl, pH 8.0, substrate 0.25 mM gemcitabine |
700510 |
| 3.5.4.5 | 0.536 |
- |
activity in non-small cell lung cancer patients with CDA Lys27Lys protein, in 50 mM beta-mercaptoethanol, 0.1 M Tris-HCl, pH 8.0, substrate 0.25 mM gemcitabine |
700510 |
| 3.5.4.5 | 3.75 |
- |
after 2.2fold purification, pH 7.5, at 25°C, using 2'-deoxycytidine as substrate |
712889 |
| 3.5.4.5 | 5.44 |
- |
after 2.3fold purification, pH 7.5, at 25°C, using cytidine as substrate |
712889 |
| 3.5.4.5 | 3558 |
- |
amplified gene |
209660 |
| 3.5.4.5 | 68.4 |
- |
amplified gene, 2'-fluoro-2'-deoxycytidine as substrate |
209660 |
